Zai Lab Ltd. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ZL-1310, a potential first-in-class Delta-like ligand (DLL3) antibody-drug conjugate $(ADC)$, for the treatment of extensive-stage small cell lung cancer (ES-SCLC). This designation is a significant milestone, highlighting the need for new treatment options in this area and facilitating the expedited development and review of ZL-1310. The company is set to initiate a pivotal study for the drug in 2025, with the aim of achieving accelerated approval by 2027. ZL-1310 is currently being evaluated in a global Phase 1a/1b clinical trial and has previously received an Orphan Drug designation for SCLC from the FDA.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.